ArticlePloS one2017
Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure.Hepatology international · 2024Guideline
- Guideline
- Immunoassay for Colistin Monitoring in Critically Ill Patients Receiving Colistin Methanesulfonate Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Colistin Therapy for Urinary Tract Infections Due to Multidrug-Resistant Bacteria: Experience at a Tertiary Academic Medical Center.Infection and drug resistance · 2026Article
- Molecular mechanisms attributed to colistin renal proximal tubular epithelial cytotoxicity.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- The power of trans-sodium crocetinate: exploring its renoprotective effects in a rat model of colistin-induced nephrotoxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- L-carnitine co-administration prevents colistin-induced mitochondrial permeability transition and reduces the risk of acute kidney injury in mice.Scientific reports · 2024Article
- Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injuryRSC pharmaceutics · 2024Article
- Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.Clinical and translational science · 2024Article
- Mid-dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients.CPT: pharmacometrics & systems pharmacology · 2023Article
- Evaluation of Potential Drug-Drug Interactions Caused by Antibacterial and Antifungal Drugs in the Intensive Care Unit: A Retrospective Cross-Sectional Study.Journal of clinical practice and research · 2023Article
- Overview of Antibiotic-Induced Nephrotoxicity.Kidney international reports · 2023Review
- Nephrotoxicity caused by colistin use in ICU: a single centre experience.BMC nephrology · 2023Observational
- The Prevalence and Risk Factors of Acute Kidney Injury during Colistin Therapy: A Retrospective Cohort Study from Lebanon.Antibiotics (Basel, Switzerland) · 2023Article
- Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review.Antibiotics (Basel, Switzerland) · 2023Review
- Utilizing liposomal encapsulation approach to address nephrotoxic challenges of colistimethate sodium through a preclinical study.Frontiers in pharmacology · 2023Article
- Incidence and Risk Factors of Colistin-Induced Nephrotoxicity Associated with The International Consensus Guidelines for the Optimal Use of the Polymyxins: A Retrospective Study in a Tertiary Care Hospital, Saudi Arabia.Antibiotics (Basel, Switzerland) · 2022Article
- The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration's Adverse Event Reporting System (FAERS) Database.Antibiotics (Basel, Switzerland) · 2022Review
- Colistin induced acute kidney injury in critically ill children: a prospective study utilizing RIFLE criteria.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2022Article
- The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study.Critical care (London, England) · 2022Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAcute kidney injury (AKI) remains a treatment-limiting toxicity of colistin. Recently developed clinical practice guidelines from the Kidney Disease: Improving Global Outcomes (KDIGO) group have harmonized definitions of AKI, but have not been widely applied to patients receiving colistin.
methodsWe retrospectively defined AKI by KDIGO definitions among adult patients receiving intravenous colistin for ≥ 3 days. Risk factors for AKI within 48 hours and 7 days of initiating colistin were determined by multivariable logistic regression.
resultsAmong 249 patients treated with colistin, rates of AKI were 12% and 29% at 48 hours and 7 days, respectively. At 48 hours, patients in the intensive care unit were at increased risk for AKI. Within 7 days, colistin daily doses >5mg/kg, chronic liver disease, and concomitant vancomycin were independent predictors. Seven percent of patients required renal replacement therapy at a median of 5 days (range: 3-7) following colistin initiation.
conclusionSafe use of colistin is promoted by early detection of AKI with KDIGO criteria, avoiding nephrotoxins, and limiting duration of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.